Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
News archive
News Archive Navigation
News Archive Navigation Language
December 2022
-
Compassionate use: Providing access to much needed treatments
What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.
-
Media ReleaseNovartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH)…
-
Media ReleaseNovartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancerEC approval based on results from pivotal Phase III VISION trial, in which Pluvicto® plus best standard of care (BSoC) significantly improved overall survival and radiographic progression-free…
-
Media ReleaseNovartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNHPhase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal nocturnal hemoglobinuria (PNH…
-
Media ReleaseNovartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapyRIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus…
-
Key ReleaseNovartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancerAd hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA–positive mCRPC who have been…
November 2022
-
Featured NewsCreating positive social change through volunteering
Over 1 billion people volunteer worldwide, sharing their skills and experience, providing support within their communities, and offering emergency assistance to those in need. On International Volunteer Day (December 5), we join forces with the UN to recognize the tireless work of all volunteers and the contributions that they make.
-
Media ReleaseNovartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malariaNovartis and Medicines for Malaria Venture (MMV) announce decision to move to Phase 3 study for novel non-artemisinin combination to treat uncomplicated malariaThis novel combination also contains an…
-
Media ReleaseNovartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASHFirst data to be presented as a late-breaker abstract from global pivotal APPLY-PNH trial of investigational oral monotherapy iptacopan in paroxysmal nocturnal hemoglobinaria (PNH), a rare and…
-
Prostate cancer and support of the care partner – Carl and Arlene’s story
When Carl was diagnosed with metastatic prostate cancer, he and his wife Arlene began navigating his cancer journey while still looking to enjoy their retirement – hoping to remain active with family and friends in their retirement community.
-
Media ReleaseNew long-term Leqvio® (inclisiran) data from Novartis show sustained efficacy and safety over four yearsResults from ORION-3 open-label trial show twice-yearly* Leqvio®(inclisiran), as a complement to statin therapy, provides effective and sustained reductions in low-density lipoprotein cholesterol (…
Pagination
- ‹ Previous page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- …
- 151
- › Next page